SHG · Clinical Research Centre/Lung Cancer CDR (Pilot)
CR
Pilot environment — synthetic demographics; real de-identified pathology sample (n=62; +80 synthetic; total 142).
Cohort Longitudinal Views

Longitudinal Analysis

Cross-patient swimmer plot, response waterfall, and Kaplan-Meier survival curves on the filtered cohort.

Cohort
Clinical stage
Driver mutation
58 patient(s) on treatment match the current filter.

Cross-Patient Swimmer Plot

One row per patient anchored at T0 = their diagnosis. Bars = treatment lines · ▲ = progression · ✕ = death · ◆ = imaging.

T06mo12moPatient #001Patient #001 · follow-up 12.5 mo (T0 = 2024-04-07)Patient #001 · Curative-intent · Surgery 2024-05-05 → 2024-06-16 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #001 · Adjuvant · Adjuvant Targeted Therapy 2024-06-16 → 2024-09-14 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #001 · 2024-10-21 (T0+197d) · CECT Thorax RECIST: NED · Tumor 0.1 cm · SUV 2.77 6-month surveillance: no evidence of recurrencePatient #001 · censored at 12.5 mo (last follow-up 2025-04-24)Patient #002Patient #002 · follow-up 12.6 mo (T0 = 2023-06-03)Patient #002 · Curative-intent · Surgery 2023-06-27 → 2023-08-08 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #002 · Adjuvant · Adjuvant Targeted Therapy 2023-08-08 → 2023-11-06 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #002 · 2023-12-20 (T0+200d) · CECT Thorax RECIST: NED · SUV 1.51 6-month surveillance: no evidence of recurrencePatient #002 · censored at 12.6 mo (last follow-up 2024-06-22)Patient #003Patient #003 · follow-up 12.5 mo (T0 = 2025-11-15)Patient #003 · Curative-intent · Surgery 2025-12-14 → 2026-01-25 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #003 · Adjuvant · Adjuvant Targeted Therapy 2026-01-25 → 2026-04-25 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #003 · 2026-05-28 (T0+194d) · CECT Thorax RECIST: NED · Tumor 0.2 cm · SUV 0.63 6-month surveillance: no evidence of recurrencePatient #003 · censored at 12.5 mo (last follow-up 2026-11-29)Patient #004Patient #004 · follow-up 12.7 mo (T0 = 2024-05-30)Patient #004 · Curative-intent · Surgery 2024-06-20 → 2024-08-01 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #004 · Adjuvant · Adjuvant Targeted Therapy 2024-08-01 → 2024-10-30 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #004 · 2024-12-19 (T0+203d) · CECT Thorax RECIST: NED · SUV 0.18 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #004 · censored at 12.7 mo (last follow-up 2025-06-22)Patient #005Patient #005 · follow-up 12.7 mo (T0 = 2024-06-19)Patient #005 · Curative-intent · Surgery 2024-07-24 → 2024-09-04 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #005 · Adjuvant · Adjuvant Targeted Therapy 2024-09-04 → 2024-12-03 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #005 · 2025-01-06 (T0+201d) · CECT Thorax RECIST: NED · SUV 1.08 6-month surveillance: stable post-treatment changesPatient #005 · censored at 12.7 mo (last follow-up 2025-07-10)Patient #006Patient #006 · follow-up 12.5 mo (T0 = 2023-07-22)Patient #006 · Curative-intent · Surgery 2023-08-23 → 2023-10-04 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #006 · Adjuvant · Adjuvant Targeted Therapy 2023-10-04 → 2024-01-02 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #006 · 2024-02-02 (T0+195d) · CECT Thorax RECIST: SD · Tumor 1.17 cm 6-month surveillance: stable post-treatment changesPatient #006 · censored at 12.5 mo (last follow-up 2024-08-05)Patient #007Patient #007 · follow-up 5.9 mo (T0 = 2023-06-10)Patient #007 · Curative · Anti-TB Therapy 2023-06-17 → 2023-09-15 (90d) 4 cycle(s) HRZE intensive phase × 2 months → HR continuation phase × 4 months (DOTS programme)Patient #007 · censored at 5.9 mo (last follow-up 2023-12-07)Patient #008Patient #008 · follow-up 12.6 mo (T0 = 2024-08-17)Patient #008 · Curative-intent · Surgery 2024-09-14 → 2024-10-26 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #008 · Adjuvant · Adjuvant Targeted Therapy 2024-10-26 → 2025-01-24 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #008 · 2025-03-04 (T0+199d) · CECT Thorax RECIST: NED · SUV 1.13 6-month surveillance: no evidence of recurrencePatient #008 · censored at 12.6 mo (last follow-up 2025-09-05)Patient #009Patient #009 · follow-up 12.5 mo (T0 = 2023-03-16)Patient #009 · Curative-intent · Surgery 2023-04-07 → 2023-05-19 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #009 · Adjuvant · Adjuvant Targeted Therapy 2023-05-19 → 2023-08-17 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #009 · 2023-09-29 (T0+197d) · CECT Thorax RECIST: NED · Tumor 0.05 cm · SUV 2.83 6-month surveillance: progression notedPatient #009 · censored at 12.5 mo (last follow-up 2024-04-01)Patient #010Patient #010 · follow-up 5.9 mo (T0 = 2025-08-15)Patient #010 · Curative · Anti-TB Therapy 2025-08-22 → 2025-11-20 (90d) 4 cycle(s) HRZE intensive phase × 2 months → HR continuation phase × 4 months (DOTS programme)Patient #010 · censored at 5.9 mo (last follow-up 2026-02-11)Patient #011Patient #011 · follow-up 12.9 mo (T0 = 2024-01-17)Patient #011 · Curative-intent · Surgery 2024-02-18 → 2024-02-19 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #011 · 2024-08-11 (T0+207d) · CECT Thorax RECIST: SD · Tumor 1.2 cm · SUV 8.4 6-month surveillance: no evidence of recurrencePatient #011 · censored at 12.9 mo (last follow-up 2025-02-12)Patient #013Patient #013 · follow-up 12.7 mo (T0 = 2023-10-21)Patient #013 · Curative-intent · Surgery 2023-11-18 → 2023-12-30 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #013 · Adjuvant · Adjuvant Targeted Therapy 2023-12-30 → 2024-03-29 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #013 · 2024-05-10 (T0+202d) · CECT Thorax RECIST: SD · Tumor 1.88 cm · SUV 2.31 6-month surveillance: progression notedPatient #013 · censored at 12.7 mo (last follow-up 2024-11-11)Patient #014Patient #014 · follow-up 12.9 mo (T0 = 2024-02-09)Patient #014 · Curative-intent · Surgery 2024-03-06 → 2024-04-17 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #014 · Adjuvant · Adjuvant Targeted Therapy 2024-04-17 → 2024-07-16 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #014 · 2024-09-04 (T0+208d) · CECT Thorax RECIST: PD · Tumor 2.3 cm · SUV 3.26 6-month surveillance: no evidence of recurrencePatient #014 · censored at 12.9 mo (last follow-up 2025-03-08)Patient #015Patient #015 · follow-up 12.7 mo (T0 = 2024-11-27)Patient #015 · Curative-intent · Surgery 2024-12-20 → 2024-12-21 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #015 · 2025-06-16 (T0+201d) · CECT Thorax RECIST: SD · Tumor 2.42 cm · SUV 2.61 6-month surveillance: stable post-treatment changesPatient #015 · censored at 12.7 mo (last follow-up 2025-12-18)Patient #016Patient #016 · follow-up 12.6 mo (T0 = 2026-01-24)Patient #016 · Curative-intent · Surgery 2026-02-18 → 2026-02-19 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #016 · 2026-08-12 (T0+200d) · CECT Thorax RECIST: SD · Tumor 1.95 cm · SUV 2.17 6-month surveillance: no evidence of recurrencePatient #016 · censored at 12.6 mo (last follow-up 2027-02-13)Patient #017Patient #017 · follow-up 12.7 mo (T0 = 2023-08-09)Patient #017 · Curative-intent · Surgery 2023-09-13 → 2023-09-14 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #017 · 2024-02-27 (T0+202d) · CECT Thorax RECIST: NED 6-month surveillance: no evidence of recurrencePatient #017 · censored at 12.7 mo (last follow-up 2024-08-30)Patient #018Patient #018 · follow-up 13 mo (T0 = 2025-02-20)Patient #018 · Curative-intent · Surgery 2025-03-18 → 2025-03-19 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #018 · 2025-09-19 (T0+211d) · CECT Thorax RECIST: PD · Tumor 4.35 cm · SUV 3.07 6-month surveillance: stable post-treatment changesPatient #018 · censored at 13 mo (last follow-up 2026-03-23)Patient #019Patient #019 · follow-up 12.6 mo (T0 = 2024-10-03)Patient #019 · Curative-intent · Surgery 2024-11-06 → 2024-11-07 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #019 · 2025-04-19 (T0+198d) · CECT Thorax RECIST: NED · SUV 0.71 6-month surveillance: stable post-treatment changesPatient #019 · censored at 12.6 mo (last follow-up 2025-10-21)Patient #020Patient #020 · follow-up 12.5 mo (T0 = 2024-04-16)Patient #020 · Curative-intent · Surgery 2024-05-16 → 2024-05-17 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #020 · 2024-10-28 (T0+195d) · CECT Thorax RECIST: NED · SUV 1.07 6-month surveillance: no evidence of recurrencePatient #020 · censored at 12.5 mo (last follow-up 2025-05-01)Patient #021Patient #021 · follow-up 12.8 mo (T0 = 2023-10-27)Patient #021 · Curative-intent · Surgery 2023-11-17 → 2023-12-22 (35d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #021 · Adjuvant · Adjuvant Chemotherapy 2023-12-22 → 2024-03-21 (90d) 4 cycle(s) Cisplatin 75mg/m² + Pemetrexed 500mg/m² Q3W × 4 cyclesPatient #021 · 2024-05-19 (T0+205d) · CECT Thorax RECIST: NED · Tumor 0.12 cm · SUV 1.25 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #021 · censored at 12.8 mo (last follow-up 2024-11-20)Patient #022Patient #022 · follow-up 13 mo (T0 = 2023-12-31)Patient #022 · Curative-intent · Surgery 2024-01-30 → 2024-03-12 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #022 · Adjuvant · Adjuvant Targeted Therapy 2024-03-12 → 2024-06-10 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #022 · 2024-07-28 (T0+210d) · CECT Thorax RECIST: NED · SUV 0.3 6-month surveillance: stable post-treatment changesPatient #022 · censored at 13 mo (last follow-up 2025-01-29)Patient #023Patient #023 · follow-up 12.5 mo (T0 = 2025-10-14)Patient #023 · Curative-intent · Surgery 2025-11-05 → 2025-12-17 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #023 · Adjuvant · Adjuvant Targeted Therapy 2025-12-17 → 2026-03-17 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #023 · 2026-04-28 (T0+196d) · CECT Thorax RECIST: SD · Tumor 2.27 cm · SUV 5.81 6-month surveillance: stable post-treatment changesPatient #023 · censored at 12.5 mo (last follow-up 2026-10-30)Patient #024Patient #024 · follow-up 12.8 mo (T0 = 2024-06-07)Patient #024 · Curative-intent · Surgery 2024-06-30 → 2024-08-04 (35d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #024 · Adjuvant · Adjuvant Chemotherapy 2024-08-04 → 2024-11-02 (90d) 4 cycle(s) Cisplatin 75mg/m² + Pemetrexed 500mg/m² Q3W × 4 cyclesPatient #024 · 2024-12-29 (T0+205d) · CECT Thorax RECIST: NED · SUV 1.26 6-month surveillance: no evidence of recurrencePatient #024 · censored at 12.8 mo (last follow-up 2025-07-02)Patient #025Patient #025 · follow-up 12.7 mo (T0 = 2025-01-04)Patient #025 · Curative-intent · Surgery 2025-02-10 → 2025-02-11 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #025 · 2025-07-26 (T0+203d) · CECT Thorax RECIST: SD · Tumor 1.95 cm · SUV 8.31 6-month surveillance: stable post-treatment changesPatient #025 · censored at 12.7 mo (last follow-up 2026-01-27)Patient #026Patient #026 · follow-up 12.5 mo (T0 = 2025-05-22)Patient #026 · Curative-intent · Surgery 2025-06-26 → 2025-07-31 (35d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #026 · Adjuvant · Adjuvant Chemotherapy 2025-07-31 → 2025-10-29 (90d) 4 cycle(s) Cisplatin 75mg/m² + Pemetrexed 500mg/m² Q3W × 4 cyclesPatient #026 · 2025-12-05 (T0+197d) · CECT Thorax RECIST: NED · Tumor 0.31 cm 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #026 · censored at 12.5 mo (last follow-up 2026-06-08)Patient #027Patient #027 · follow-up 5.9 mo (T0 = 2024-01-23)Patient #027 · Curative · Anti-TB Therapy 2024-01-30 → 2024-04-29 (90d) 4 cycle(s) HRZE intensive phase × 2 months → HR continuation phase × 4 months (DOTS programme)Patient #027 · censored at 5.9 mo (last follow-up 2024-07-21)Patient #029Patient #029 · follow-up 12.6 mo (T0 = 2023-02-18)Patient #029 · Curative-intent · Surgery 2023-03-12 → 2023-03-13 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #029 · 2023-09-04 (T0+198d) · CECT Thorax RECIST: NED · Tumor 0.05 cm · SUV 0.7 6-month surveillance: no evidence of recurrencePatient #029 · censored at 12.6 mo (last follow-up 2024-03-07)Patient #030Patient #030 · follow-up 12.6 mo (T0 = 2025-07-28)Patient #030 · 1L · Chemo-Immunotherapy 2025-08-17 → 2025-11-15 (90d) 4 cycle(s) Carboplatin AUC5 + Pemetrexed 500mg/m² + Pembrolizumab 200mg Q3W × 4 cycles, then maintenance Pemetrexed + Pembrolizumab (KEYNOTE-189)Patient #030 · 2025-10-12 (T0+76d) · CECT Thorax/Abdomen RECIST: PR · Tumor 1.39 cm · SUV 12.94 Re-staging scan: target lesions decreased ~35% compared to baselinePatient #030 · 2026-02-13 (T0+200d) · CECT Thorax RECIST: NED · Tumor 0.04 cm · SUV 2.85 6-month surveillance: stable post-treatment changesPatient #030 · censored at 12.6 mo (last follow-up 2026-08-17)Patient #031Patient #031 · follow-up 12.6 mo (T0 = 2023-09-06)Patient #031 · 1L · Chemo-Immunotherapy 2023-09-24 → 2023-12-23 (90d) 4 cycle(s) Carboplatin AUC5 + Pemetrexed 500mg/m² + Pembrolizumab 200mg Q3W × 4 cycles, then maintenance Pemetrexed + Pembrolizumab (KEYNOTE-189)Patient #031 · 2023-11-19 (T0+74d) · CECT Thorax/Abdomen RECIST: SD · Tumor 1.83 cm · SUV 8.41 Re-staging scan: target lesions progression compared to baselinePatient #031 · 2024-03-22 (T0+198d) · CECT Thorax RECIST: NED · Tumor 0.07 cm · SUV 1.96 6-month surveillance: stable post-treatment changesPatient #031 · censored at 12.6 mo (last follow-up 2024-09-23)Patient #032Patient #032 · follow-up 12.8 mo (T0 = 2023-03-08)Patient #032 · 1L · Chemo-Immunotherapy 2023-04-02 → 2023-07-01 (90d) 4 cycle(s) Carboplatin AUC5 + Pemetrexed 500mg/m² + Pembrolizumab 200mg Q3W × 4 cycles, then maintenance Pemetrexed + Pembrolizumab (KEYNOTE-189)Patient #032 · 2023-05-28 (T0+81d) · CECT Thorax/Abdomen RECIST: PR · Tumor 1.94 cm · SUV 4.98 Re-staging scan: target lesions decreased ~35% compared to baselinePatient #032 · 2023-09-29 (T0+205d) · CECT Thorax RECIST: PD · Tumor 2.61 cm · SUV 6.36 6-month surveillance: stable post-treatment changesPatient #032 · censored at 12.8 mo (last follow-up 2024-04-01)Patient #033Patient #033 · follow-up 13 mo (T0 = 2024-10-02)Patient #033 · Curative-intent · Surgery 2024-10-27 → 2024-10-28 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #033 · 2025-05-01 (T0+211d) · CECT Thorax RECIST: PD · Tumor 2.85 cm · SUV 2.5 6-month surveillance: no evidence of recurrencePatient #033 · censored at 13 mo (last follow-up 2025-11-02)Patient #034Patient #034 · follow-up 12.8 mo (T0 = 2025-11-20)Patient #034 · 1L · Targeted Therapy 2025-12-14 → 2026-10-01 (291d) 13 cycle(s) Alectinib 600mg PO BD (ALEX trial regimen)Patient #034 · 2L · Chemotherapy 2026-10-01 → 2026-12-30 (90d) 4 cycle(s) Docetaxel 75mg/m² + ramucirumab 10mg/kg Q3W (REVEL)Patient #034 · 2026-02-08 (T0+80d) · CECT Thorax/Abdomen RECIST: PR · Tumor 4.27 cm · SUV 6.35 Re-staging scan: target lesions stable compared to baselinePatient #034 · 2026-06-12 (T0+204d) · CECT Thorax RECIST: SD · Tumor 3.93 cm · SUV 5.94 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #034 · Progression at 9.9 mo (T0+301d)Patient #034 · censored at 12.8 mo (last follow-up 2026-12-14)Patient #035Patient #035 · follow-up 12.7 mo (T0 = 2024-08-06)Patient #035 · Curative-intent · Surgery 2024-09-06 → 2024-10-18 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #035 · Adjuvant · Adjuvant Targeted Therapy 2024-10-18 → 2025-01-16 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #035 · 2025-02-25 (T0+203d) · CECT Thorax RECIST: SD · Tumor 4.29 cm · SUV 8.21 6-month surveillance: stable post-treatment changesPatient #035 · censored at 12.7 mo (last follow-up 2025-08-29)Patient #036Patient #036 · follow-up 12.9 mo (T0 = 2025-12-07)Patient #036 · Curative-intent · Surgery 2026-01-12 → 2026-01-13 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #036 · 2026-07-03 (T0+208d) · CECT Thorax RECIST: PD · Tumor 2.99 cm · SUV 8.11 6-month surveillance: stable post-treatment changesPatient #036 · censored at 12.9 mo (last follow-up 2027-01-04)Patient #037Patient #037 · follow-up 12.6 mo (T0 = 2023-04-17)Patient #037 · Curative-intent · Surgery 2023-05-11 → 2023-06-22 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #037 · Adjuvant · Adjuvant Targeted Therapy 2023-06-22 → 2023-09-20 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #037 · 2023-11-03 (T0+200d) · CECT Thorax RECIST: NED · SUV 1.85 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #037 · censored at 12.6 mo (last follow-up 2024-05-06)Patient #038Patient #038 · follow-up 12.8 mo (T0 = 2025-04-11)Patient #038 · Curative-intent · Surgery 2025-05-05 → 2025-06-16 (42d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #038 · Adjuvant · Adjuvant Targeted Therapy 2025-06-16 → 2025-09-14 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #038 · 2025-11-01 (T0+204d) · CECT Thorax RECIST: NED · SUV 1.41 6-month surveillance: new indeterminate nodule for short-interval follow-upPatient #038 · censored at 12.8 mo (last follow-up 2026-05-05)Patient #039Patient #039 · follow-up 12.8 mo (T0 = 2024-02-10)Patient #039 · Curative-intent · Surgery 2024-03-15 → 2024-04-26 (42d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #039 · Adjuvant · Adjuvant Targeted Therapy 2024-04-26 → 2024-07-25 (90d) 4 cycle(s) Osimertinib 80mg PO OD x 3 years (ADAURA regimen)Patient #039 · 2024-09-02 (T0+205d) · CECT Thorax RECIST: PD · Tumor 3.73 cm · SUV 15.71 6-month surveillance: progression notedPatient #039 · censored at 12.8 mo (last follow-up 2025-03-06)Patient #040Patient #040 · follow-up 12.5 mo (T0 = 2023-02-15)Patient #040 · 1L · Targeted Therapy 2023-03-03 → 2024-01-14 (317d) 15 cycle(s) Osimertinib 80mg PO OD (3rd-gen EGFR TKI; FLAURA)Patient #040 · 2L · Targeted Therapy 2024-01-14 → 2024-09-10 (240d) 11 cycle(s) Switch to amivantamab + lazertinib (post-osimertinib resistance)Patient #040 · 2023-04-28 (T0+72d) · CECT Thorax/Abdomen RECIST: SD · Tumor 2.62 cm · SUV 12.46 Re-staging scan: target lesions decreased ~15% compared to baselinePatient #040 · 2023-08-30 (T0+196d) · CECT Thorax RECIST: NED · Tumor 0.04 cm · SUV 2.64 6-month surveillance: no evidence of recurrencePatient #040 · Progression at 10.2 mo (T0+310d)Patient #040 · censored at 12.5 mo (last follow-up 2024-03-02)Patient #041Patient #041 · follow-up 12.5 mo (T0 = 2025-11-13)Patient #041 · Curative-intent · Surgery 2025-12-07 → 2025-12-08 (1d) VATS right/left lobectomy with mediastinal lymph node dissection. R0 resection achieved.Patient #041 · 2026-05-26 (T0+194d) · CECT Thorax RECIST: NED 6-month surveillance: no evidence of recurrencePatient #041 · censored at 12.5 mo (last follow-up 2026-11-27)Patient #042Patient #042 · follow-up 12.6 mo (T0 = 2023-05-04)Patient #042 · Curative-intent · Surgery 2023-06-04 → 2023-07-09 (35d) Open lobectomy with systematic lymphadenectomy. Margins clear (R0).Patient #042 · Adjuvant · Adjuvant Chemotherapy 2023-07-09 → 2023-10-07 (90d) 4 cycle(s) Cisplatin 75mg/m² + Pemetrexed 500mg/m² Q3W × 4 cyclesPatient #042 · 2023-11-20 (T0+200d) · CECT Thorax RECIST: NED · SUV 0.85 6-month surveillance: progression notedPatient #042 · censored at 12.6 mo (last follow-up 2024-05-23)

Response Waterfall

Best % change in tumour size from baseline per patient. PR = ≤ −30%, PD = ≥ +20%.

n = 58 patient(s) with paired imaging.

Kaplan-Meier — OS & PFS

Survival curves on the filtered cohort. n = 58 · 0 death event(s) · 3 progression event(s). Deceased / progression-free patients are censored at last follow-up.